We are live on ! Find out more
NCM

NEXTBio Capital Management Portfolio holdings

AUM $217M
This Fund
S&P 500
This Quarter Est. Return
+20%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$215M
AUM Growth
+$44.9M
Cap. Flow
+$21.8M
Cap. Flow %
10.13%
Top 10 Hldgs %
71.05%
Holding
24
New
1
Increased
9
Reduced
7
Closed
–

Top Buys

Rank Stock Value
1
CMPS
Compass Pathways
CMPS
+$8.53M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$5.69M
3
GPCR icon
Structure Therapeutics
GPCR
+$2.66M
4
ZBIO
Zenas BioPharma
ZBIO
+$2.35M
5
TERN
Terns Pharmaceuticals
TERN
+$2.19M

Top Sells

Rank Stock Value
1
CMPX icon
Compass Therapeutics
CMPX
+$1.53M
2
ORIC icon
Oric Pharmaceuticals
ORIC
+$1.05M
3
EVMN
Evommune Inc
EVMN
+$1,000K
4
XENE icon
Xenon Pharmaceuticals
XENE
+$22.1K
5
PCVX icon
Vaxcyte
PCVX
+$14.2K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TERN
1
DELISTED
Terns Pharmaceuticals
TERN
$31.9M 14.8%
604,534
+53,344
+10% +$2.19M
PTGX icon
2
Protagonist Therapeutics
PTGX
$9.34B
$24.2M 11.24%
229,619
– –
STTK icon
3
Shattuck Labs
STTK
$707M
$20.3M 9.4%
3,149,907
– –
VOR icon
4
Vor Biopharma
VOR
$1.34B
$17.8M 8.28%
999,967
– –
CMPS
5
Compass Pathways
CMPS
$1.9B
$11.2M 5.19%
2,021,407
+1,268,776
+169% +$8.53M
RYTM icon
6
Rhythm Pharmaceuticals
RYTM
$7.38B
$11M 5.09%
126,078
+58,492
+87% +$5.69M
XENE icon
7
Xenon Pharmaceuticals
XENE
$5.81B
$10.7M 4.95%
183,225
-479
-0.3% -$22.1K
PVLA
8
Palvella Therapeutics
PVLA
$2.16B
$10.3M 4.79%
82,686
– –
ZBIO
9
Zenas BioPharma
ZBIO
$2.04B
$8.34M 3.87%
426,736
+104,753
+33% +$2.35M
IVA
10
Inventiva
IVA
$1.11B
$7.4M 3.44%
1,333,484
+34,783
+3% +$212K
VSTM icon
11
Verastem
VSTM
$654M
$6.93M 3.22%
1,306,800
-530
-0% -$3.27K
CBIO
12
Crescent Biopharma
CBIO
$659M
$6.85M 3.18%
372,856
– –
ORIC icon
13
Oric Pharmaceuticals
ORIC
$1.37B
$6.63M 3.08%
523,619
-92,101
-15% -$1.05M
GPCR icon
14
Structure Therapeutics
GPCR
$3.38B
$6.42M 2.98%
133,239
+38,796
+41% +$2.66M
PCVX icon
15
Vaxcyte
PCVX
$8.9B
$5.53M 2.57%
95,223
-262
-0.3% -$14.2K
COGT icon
16
Cogent Biosciences
COGT
$6.02B
$5.05M 2.34%
131,188
+35,369
+37% +$1.31M
CMPX icon
17
Compass Therapeutics
CMPX
$432M
$4.49M 2.08%
848,204
-265,801
-24% -$1.53M
EVMN
18
Evommune Inc
EVMN
$480M
$4.23M 1.96%
184,063
-44,223
-19% -$1,000K
OCS icon
19
Oculis Holding
OCS
$678M
$3.98M 1.85%
149,592
-158
-0.1% -$4.18K
ZLAB icon
20
Zai Lab
ZLAB
$2.93B
$3.45M 1.6%
183,362
+20,000
+12% +$371K
IRON icon
21
Disc Medicine
IRON
$3.07B
$3.37M 1.56%
52,655
+9,877
+23% +$685K
KALV
22
DELISTED
KalVista Pharmaceuticals
KALV
$2.65M 1.23%
131,796
– –
SMMT icon
23
Summit Therapeutics
SMMT
$11B
$1.7M 0.79%
+89,717
New +$1.45M
ACET icon
24
Adicet Bio
ACET
$84.8M
$1.07M 0.5%
157,827
– –

Similar funds

HIMS
Hager Investment Management Services New London, New Hampshire $217M AUM 56.89% 1-Year Est. Return
CWM
Carolina Wealth Management Greenville, North Carolina $217M AUM
PP
Pearl Planning Dexter, Michigan $217M AUM
WWM
Wolff Wiese Magana Carslbad, California $217M AUM 47.64% 1-Year Est. Return
CA
Corrado Advisors Ramsey, New Jersey $217M AUM 26.96% 1-Year Est. Return
ECM
English Capital Management Bloomfield Hills, Michigan $217M AUM 37.8% 1-Year Est. Return
RFM
RPD Fund Management New York $218M AUM 48.33% 1-Year Est. Return
DCM
Delta Capital Management Red Bank, New Jersey $217M AUM 67.79% 1-Year Est. Return

NEXTBio Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, NEXTBio Capital Management held 24 positions worth $215M, up 26% from $170M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

NEXTBio Capital Management deployed $21.8M of net new capital in Q1 2026, opening 1 new position and adding to 9 existing holdings. Its largest new stake was Summit Therapeutics: 89,717 shares worth $1.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Compass Therapeutics, an estimated $1.53M trimmed.

  • NEXTBio Capital Management's largest Q1 2026 buy was Summit Therapeutics: 89,717 shares worth $1.7M.
  • NEXTBio Capital Management added most to Compass Pathways in Q1 2026, an estimated $8.53M increase.
  • NEXTBio Capital Management's biggest Q1 2026 reduction was Compass Therapeutics, cutting an estimated $1.53M.
  • NEXTBio Capital Management's ten largest holdings make up 71% of its $215M portfolio in Q1 2026.
  • NEXTBio Capital Management opened 1 new position and closed 0 in Q1 2026.
  • NEXTBio Capital Management's portfolio value rose 26% quarter-over-quarter to $215M.

Based on NEXTBio Capital Management's 13F filing for Q1 2026, filed 14 May 2026.